Archive for January, 2021
During the last weeks of December 2020, China’s benchmark iron futures decreased after the nation called for the steel industry to manufacture less crude steel this year. The objective of this is in line with the Chinese government’s carbon neutrality plan.
Last year, prices of iron ore more than doubled, which set the ore that is used to make steel on track to becoming the top-performing major product in the world for the second year in a row. This came at a time when Chinese demand stands firm and speculative money was being received by the market.
Despite this, however, the Ministry of Industry and Information Technology urged the steel sector to purposely decrease the output of crude steel and make sure that an annual decrease was registered this year. Dalian Commodity Exchange’s most active iron futures gained 37.8% during the last quarter of 2020, having gained 21.5% last month alone.
China was the biggest producer of steel in the world, producing 1.1 billion tons of steel last year. Between 2016 and 2020, the country has discontinued 150 million tons of yearly production capacity.
China International Trust Investment Corporation told Reuters that a further decrease in output would further improve the demand-and-supply situation of the country’s steel sector. This would resolve issues of deformed profits caused by high prices of raw materials. The corporation added that managing steel production would help protect the profit margins of mills while preventing high prices from moving into the downstream sectors.
For May delivery, the futures traded on the Dalian Commodity Exchange the most closed down 3.5% to 984 yuan, or approximately $150, per ton. This figure was the lowest that had been recorded in close to a month.
After losing 4.7% in early trade, futures of coking coal decreased a further 3.3% to 1,641 yuan a ton. On the other hand, futures of Dalian coke dropped by 0.1% to 2,822 yuan per ton.
In September 2020, President Xi Jinping of China had announced that the country planned to go carbon neutral by the year 2060. China is currently the world’s biggest emitter of greenhouse gases as well as the biggest consumer of energy. The country is also the lead importer of both natural gas and oil. In addition to this, China also mines and burns half of the coal produced worldwide.
Sanford C. Bernstein & Co approximates that transitioning the economy of China to carbon neutrality in four decades may cost $5.5 trillion.
Back in the United States, several mining firms are having a good run. For instance, Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) uses two different technologies to extract uranium at three facilities located in Utah, Wyoming and Texas.
NOTE TO INVESTORS: The latest news and updates relating to Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) are available in the company’s newsroom at http://ibn.fm/UUUU
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
A new study conducted by researchers from Sweden’s Karolinska Institutet describes how macrophages, which are different kinds of immune cells, can develop in the lungs and cause serious lung diseases.
Macrophages have many functions in the body, including protecting the lungs from attacks by bacteria and viruses. The lungs’ structure exposes them to both these pathogens through blood and air. However, under specific conditions, the macrophages can also cause severe lung disease such as the coronavirus and COPD (chronic obstructive pulmonary disease). However, research on human lung macrophages development is scanty.
Macrophages develop from a type of white blood cell known as monocytes. There are two types of monocytes in humans: CD16+ monocytes (nonclassical) and CD14+ monocytes (classical).
The researchers used a model to directly study lung-macrophages development in a living lung. The study was conducted in combination with a method to study RNA sequencing and individual cells gene activity, which led to the discovery of how blood monocytes developed into lung macrophages in humans. The study was reported in “Immunity” and may help in the development of future treatments for the coronavirus.
Tim Willinger, the study lead and an associate professor at the Institutet’s Department of Medicine, stated that the study demonstrated that classical monocytes moved into lung tissue and airways and are transformed into macrophages. These macrophages then protect the function and health of the lungs. He explained that the researchers had identified HLA-DRhi, an immune cell that’s an intermediate airway macrophage and blood monocyte. The researchers observed that these monocytes could leave the blood circulation and move into the lung tissue. Unlike these monocytes, CD16+ monocytes do not move into lung tissue despite developing into macrophages in the lungs’ blood vessels.
Elza Evren, the first author of the study, stated that in respiratory infections, monocytes found in the lungs grow into macrophages to help fight the bacteria and viruses. However, some specific macrophage types could also lead to infections and severe inflammation in the lungs.
The researchers believe that if an individual is infected with COVID-19, the virus that causes it, SARS-CoV-2, causes macrophages that prevent inflammation in the lungs to be replaced by lung macrophages that encourage inflammation instead.
Willinger explained that other studies had shown that the existence of macrophages derived from blood monocytes corresponded with how seriously ill an individual became when infected with the coronavirus in addition to how extensively the individual’s lungs were damaged.
Meanwhile, other biotech companies are also pressing ahead with finding remedies to other health threats. For example, AzurRx BioPharma Inc. (NASDAQ: AZRX) is focused on using recombinant proteins to develop therapies for gastrointestinal conditions.
NOTE TO INVESTORS: The latest news and updates relating to AzurRx BioPharma Inc. (NASDAQ: AZRX) are available in the company’s newsroom at https://ibn.fm/AZRX
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today issued a letter to its shareholders and the investment community from its CEO and President James Sapirstein. The letter discusses AzurRx BioPharma’s optimism and enthusiasm for 2021 and its extraordinary accomplishments in the face of so many recent challenges. “This year, already, we are building on the momentum and wasted no time in making an impact with the announcement of a transformative in-licensing agreement with First Wave Bio, bringing in a new asset and two new GI indications into our development fold,” Sapirstein states in the letter. “AzurRx is a fundamentally stronger company today compared to 12 months ago, from a strategic, operational and financial perspective. We now have three targeted, non-systemic clinical-stage GI assets in our pipeline that address significant unmet clinical needs in potential billion-dollar markets. I believe we are poised to increase shareholder value. The Company recently raised capital in order to pay for the up-front licensing opportunity, without having to impact the budget for our MS1819 clinical timelines. In the long run, AzurRx is much better positioned to provide valuable products with significant market opportunities into the GI space.”
To view the full press release, visit http://ibn.fm/F5UBw
About AzurRx BioPharma Inc.
AzurRx BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases. The company has a pipeline of three gut-restricted GI assets. The first is MS1819, a recombinant lipase biologic for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis, with two ongoing phase 2 clinical trials. The other two are clinical-stage therapies using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor: FW-420, for the treatment of grade 1 immune checkpoint inhibitor associated colitis (“ICI-AC”) and diarrhea in oncology patients, and FW-1022, for the treatment of COVID-19 gastrointestinal infections. The company is headquartered in Delray Beach, Florida, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.
NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at http://ibn.fm/AZRX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Loop Insights (TSXV: MTRX) (OTCQB: RACMF), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement and automated venue tracing to the brick-and-mortar space, today announced its collaboration with bdG Sports. According to the update, Loop Insights was selected by bdG to provide its venue management platform to the Big West Conference Men’s and Women’s Basketball Championships being held at the Mandalay Bay Events Center in Las Vegas from March 9-13, 2021. “Loop Insights is proud to be selected once again as the venue management provider for bdG Sports and the Big West Conference Championships,” said Loop Insights CEO Rob Anson. The successful deployments of our venue management platform at the Gulf Coast Showcase and Vegas Main Event clearly demonstrate our ability to secure any venue through our complete end-to-end venue management solution. We look forward to working with bdG Sports once again to protect NCAA athletes, coaches, and staff.”
To view the full press release, visit https://ibn.fm/1LntO
About Loop Insights Inc.
Loop Insights is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing and contactless solutions to the brick-and-mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network and sold through the TELUS IoT Marketplace. For more information, visit the company’s website at www.LoopInsights.ai.
NOTE TO INVESTORS: The latest news and updates relating to RACMF are available in the company’s newsroom at http://ibn.fm/RACMF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced its receipt of notice from The Nasdaq Stock Market on Jan. 5, 2021, that VistaGen has regained compliance with the minimum bid price requirement. The requirement is under Nasdaq Listing Rule 5550(a)(2) (the Bid Price Rule) for continued listing on The Nasdaq Capital Market. According to the update, VistaGen is now in full compliance with all applicable listing standards, and Nasdaq considers the matter closed.
To view the full press release, visit http://ibn.fm/SrDlE
About VistaGen Therapeutics Inc.
VistaGen is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at http://ibn.fm/VTGN
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- Strong growth in US lumber demand has led to both record price increases – and record levels of timber, tree debris along with it
- Sustainable Green Team has sought to introduce environmentally sustainable solution to storm, tree debris removal sector
- Via purchase of Mulch Manufacturing in February 2020, SGTM is now able to process tree biomass it collects into premium mulch products
- SGTM has perfected its vertically integrated business model – retailing environmentally friendly agricultural product while simultaneously getting compensated for collecting necessary raw materials
Lumber demand in the United States has never been higher; according to the National Association of Home Builders (“NAHB”), lumber prices rose by 30 percent between the onset of Hurricane Harvey in August 2017 and January 2018 on the back of strong reconstruction-driven demand (https://ibn.fm/ncKQM). However, recent price trends have put even that rally to shame. Since mid-April 2020, lumber prices have risen by over 130% (https://ibn.fm/5Oh35), with the Covid-19 pandemic driving a virtual exodus of residents from large urban metropolis’ and spurring a wave of new housing starts elsewhere in the country. However, the phenomenon has also led to record levels of timber wastage – leading to a sharp increase in the demand for the Sustainable Green Team (OTC: SGTM), a vertically integrated storm and debris removal company’s services.
Sustainable Green Team has historically sought to provide a synergistic and environmentally beneficial solution to tree and storm waste disposal, in a bid to alleviate the environmental burdens which have traditionally afflicted landfills and disposal sites around the country. Accordingly, throughout its 40-year corporate tenure, SGTM has worked to cultivate a reputation as an environmentally responsible enterprise, focused on being “stewards of the environment” across all aspects of their business.
A perennial challenge for SGTM and its peer companies within the sector has been to find a sustainable solution for the treatment and handling of tree debris, which has habitually been sent to local landfills and disposal sites. The company sought to address this issue through the purchase of Ohio-based Mulch Manufacturing, a leader in the field of manufacturing mulch used for agricultural and landscaping purposes in February 2020 (https://ibn.fm/A70mT).
Following its merger with Mulch Manufacturing, SGTM has been able to move beyond the traditional waste disposal model, rather opting to process the collected tree biomass into a variety of organic, attractive, and next-generation mulch products which are packaged and sold on to retailers, landscapers, installers and garden centers. Sold under the Softscape(R) brand name, Mulch Manufacturing’s mulch and landscaping products allow water and air to penetrate soil and roots, a vital function to promote plant health and growth (https://ibn.fm/F2qid).
SGTM has been able to translate its acquisition into ongoing commercial success, recently revealing that its subsidiary, Mulch Manufacturing Inc., had been awarded contracts to supply The Kroger Co. and Alimentation Couch-Tard’s Circle K subsidiary with premium grade organic mulch products over the course of 2021 (https://ibn.fm/5eMeP).
In addition to its efforts in recycling tree and storm waste into commercialized mulch products, the Sustainable Green Team has recently gained the International Play Equipment Manufacturers Association (“IPEMA”) certification to commence recycling waste into playground surfacing material. With demand for playground surfacing material rapidly rising as a result of growing demand from the likes of schools, commercial athletic facilities and recreational spaces, SGTM’s new product line is expected to help the company tap into a market which is estimated to rise to a value of over $5.8 billion by the end of 2026, a 150% increase from 2017’s $3.7 billion (https://ibn.fm/OlJEM).
As environmental concerns continue to build across the world, the need to find sustainable solutions within the tree and debris management sector has gained increased prominence. Through its vertically integrated structure, SGTM has now managed to achieve the rarest goal of them all – building a sustainable and commercially viable business in an increasingly essential sector of the economy.
To learn more about Sustainable Green Team, please visit www.NationalArborCare.com and view the investor presentation at https://ibn.fm/dL5kn
NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its wholly owned subsidiary Helomics has completed the integration of Quantitative Medicine’s (“QM”) novel active-learning Computational Research Engine (CoRE(TM)). According to the update, CoRE was integrated with Helomics’ proprietary TumorSpace(TM) knowledgebase of 150,000 tumor drug response profiles and the TruTumor(TM) patient primary tumor cell line assay. The move allows Helomics to offer a revolutionary new AI-driven patient-centric drug discovery service to pharmaceutical companies that will significantly improve the chances of successfully translating new drugs into the clinic. “With the completion of the CoRE integration, we are now able to offer our new PeDAL(TM) (Patient-cEntric Discovery by Active Learning) service to pharmaceutical companies to allow patient-centric de-risking of compounds early in discovery, resulting in better prioritization of compounds and better coverage of patient diversity. This will dramatically improve the chances of successfully translating discoveries into the clinic, resulting in lowered costs, shortened timelines, and most importantly enhanced ‘speed-to-patient’ for new therapies,” explained Dr. Carl Schwartz, CEO of Predictive Oncology. “We expect to see revenue generating projects that use PeDAL and CoRE in the first half of 2021.”
To view the full press release, visit http://ibn.fm/u5Hle
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement, and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
iClick Interactive (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, has launched a powerful off-the-shelf (standard) SaaS enterprise management platform. Called iSCRM, the platform is designed for daily operations and social customer relationship management. iSCRM helps customers attract new users and manage private traffic through leveraging updated features and various functions on WeCom, WeChat and WeChat Mini Program. In addition, iSCRM allows users to fully track consumer actions from all touch-points within the Tencent ecosystem, establishes real-time 360-degree consumer profiles through data analytics, offers purchase and frequency analysis and advising on data-driven personalized engagement strategies, digitizes sales management and evaluation, and ensures seamless consumer transfer to retain valuable consumers and lower the churn rate when sales representatives leave companies. “I am very excited to announce the launch of iSCRM, iClick’s first standard SaaS product,” said iClick co-founder and CEO Jian “T.J.” Tang in the press release. “This new solution equips clients with the latest smart tools that integrates and optimizes the various functions of Tencent’s continuously evolving ecosystem. We believe iSCRM has great potential to enhance brands’ private domain traffic management and generate higher sales revenues. We will continue to develop leading edge products like iSCRM that empower brands to take advantage of the latest trends in the smart retail era and look forward to the contribution of such standard products to rapidly scaling up iClick’s sales revenue across our mid-tier client base.”
To view the full press release, visit http://ibn.fm/m17TR
About iClick Interactive Asia Group Limited
iClick Interactive is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, the company’s proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in 10 locations worldwide including Asia and Europe. For more information about the company, please visit www.iClick.com.
NOTE TO INVESTORS: The latest news and updates relating to ICLK are available in the company’s newsroom at http://ibn.fm/ICLK
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, has provided an update on its patent filings. The company has eight filings, all tied to Cybin’s novel therapeutics, delivery mechanisms and treatment regiments. The patent updates noted that Cybin has patent applications for the following: a provisional patent application for an oral film delivery mechanism covering all psychedelic molecules delivered through oral films; a delivery technology covering various chemically synthesized psychedelic molecules; multiple patent applications for deuterated psychedelic molecules and analogues; and a patent application for platforms that create supportive treatment regimens. The company also announced that it is working to develop its therapeutics program. Planned expansion includes adding psychedelic compounds such as DMT, psilocybin analogues and a range of tryptamines and phenylethylamines to psilocybin, which is already in development. Cybin is also planning to build a database of molecules and their chemically synthesized pathways to be used in the pharmaceutical industry. “Our management team has a proven track record in developing and commercializing dozens of therapeutics, including a modified psychedelic targeted for treatment resistant depression and we intend to continue to advance our IP portfolio, drug discovery platform, delivery mechanisms and technologies all with the end goal of enhancing the patient experience and progressing the psychedelic industry,” said Cybin CEO Doug Drysdale in the press release.
To view the full press release, visit http://ibn.fm/lJGkC
About Cybin Inc.
Cybin is a life sciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems, aiming to improve bioavailability, to potentially achieve the desired medicinal effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at http://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Researchers from Wistar Institute have found a new category of compounds that merge the killing of bacterial pathogens that are drug resistant through the use of antibiotics, with a swift immune response used to fight antimicrobial resistance.
Last year, the WHO declared antimicrobial resistance (AMR) as a top public health threat. Estimates show that by the year 2050, infections that are antibiotic resistant could not only thrust upon the world economy a collective burden of $100 trillion but also claim the lives of nearly 10 million people every year. It does not help that the number of bacteria growing treatment resistant with the current antibiotics is increasing, with few new drugs in development. This has created a desperate need for better antibiotics to be developed in a bid to avert public health crisis.
The lead author of the study, who also happens to be an assistant professor in the Vaccine and Immunotherapy Center, Farokh Dotiwala explained that the researchers used a bilateral and creative approach to create novel molecules that may be used to eliminate infections that are challenging to treat while also boosting an individual’s immune response. The main objective of the study was to discover dual-acting immune antibiotics. The study’s findings were reported in the “Nature” journal.
The antibiotics being used at the moment typically target vital bacterial functions such as metabolic pathways, as well as protein and nucleic acid synthesis. However, through bacterial mutations that the antibiotics target, bacteria can gain a resistance to the drugs. This either pumps the drugs out or inactivates them.
Dotiwala stated that the scientists rationalized that using the immune system to target bacteria in different areas at the same time would make it difficult for the bacteria to develop resistance to the antibiotics.
Dotiwala and his colleagues centered their focus on a non-mevalonate pathway that is not present in humans but is vital for a majority of bacteria. This made it the best target for development of antibiotics. The pathway is in charge of the biogenesis of molecules needed in a majority of pathogenic bacteria for cell survival.
Dotiwala then partnered with the other senior author of the study and Wistar’s medicinal chemist Joseph Salvino to discover and synthesize novel molecules of IspH inhibitors that could penetrate the cell walls of the bacteria.
This approach helped the researchers show that the inhibitors triggered stronger bacterial elimination activity in the immune system. The first author of the study, Kumar Singh, explained that activation of the immune system made up another line of defense of the dual-acting immuno-antibiotics strategy.
It is also noteworthy to follow news about CNS Pharmaceuticals Inc. (NASDAQ: CNSP). This biotech company recently completed a phase 1 clinical trial of a drug candidate, and results show that at least 44% of the participants benefited from the potential treatment for malignant brain tumors.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that it will participate in the virtual H.C. Wainwright BioConnect Conference taking place on Jan. 11-14, 2021. According to the update, AzurRx BioPharma president and CEO James Sapirstein will take part in virtual one-on-one meetings with registered investors and pharmaceutical companies. Sapirstein will be available to provide an overview of the company’s business and clinical development programs, as well as discuss anticipated 2021 milestones. Interested parties should visit https://ibn.fm/bNYP3 to register for the event.
To view the full press release, visit: https://ibn.fm/8xntU
About AzurRx BioPharma Inc.
AzurRx BioPharma is a biopharmaceutical company specialized in the research and development of non-systemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial, and the Combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. The company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.
NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at http://ibn.fm/AZRX
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, on Tuesday announced that it will present at the H.C. Wainwright Bioconnect 2021 Conference. According to the update, the presentation will be available on-demand throughout the event from Jan. 11-14, 2021, starting at 6:00 a.m. ET. In addition, a webcast of the presentation will be available via the IR section of the company’s website and will be archived and accessible for at least 90 days.
To view the full press release, visit http://ibn.fm/oz6JA
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor), with its lead program in phase 2b/3 clinical trials. For more information, visit the company’s website at www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- U.S. taking actionable steps toward acceptance of psilocybin
- States, individual cities have decriminalized, made use and possession of psilocybin low law-enforcement priority
- More psilocybin research being done focused on health, well-being of Americans facing a mental health crisis on epic levels
Cybin (NEO: CYBN) is a life science company focused on the pharmaceutical development of psychedelic products. The company’s subsidiary Serenity Life Sciences is focused on the research and development of psilocybin-based medications. Psilocybin, referred to by the media as magic mushrooms, has had its share of bad press. The stigma of this substance has halted R&D in America in the past, but that is beginning to change.
Under the Controlled Substances Act, psilocybin is included with heroin and LSD as a Schedule I drug. According to the National Drug Intelligence Center, psilocybin serves no legitimate medical purpose in the United States (https://ibn.fm/Z23k3). This view has come under criticism as recent studies surrounding the substance show otherwise. The public’s opinion, state guidelines and pharmaceutical development of psychedelic products are moving towards growing acceptance and legalization.
Oregon became the first state to legalize the use of psilocybin for therapeutic use when voters passed Measure 109 on Nov. 3, 2020 (https://ibn.fm/TKCuc), the latest in several steps the country hs been taking toward psilocybin acceptance.
In 2005 the Court of Appeals in New Mexico overturned a felony drug trafficking conviction by citing that growing hallucinogenic mushrooms isn’t prohibited under the drug trafficking law’s definition of “manufacture” (https://ibn.fm/yRUSw), marking one of the first indications of what would be a slow-changing tide. Fifteen years later, New Jersey amended a marijuana decriminalization bill to include a lesser punishment for possession of psilocybin from a third-degree felony to a disorderly persons offense (https://ibn.fm/dmb3p).
In addition, where states are not decriminalizing psilocybin, individual cities are. Denver was the first U.S. city to decriminalize psilocybin mushrooms. Ordinance 301 was passed with a 50.56% majority in May 2019 (https://ibn.fm/pX7ii). This ordinance keeps the city from prosecuting or arresting adults in possession of or even growing the mushrooms.
Other cities across the country have followed suit. Oakland, California, passed a law the following month banning law enforcement from investigating and prosecuting individuals using or possessing drugs sourced from plants, cacti and mushrooms that contain psilocybin (https://ibn.fm/nEBhR).
The third city was also in California. Santa Cruz’s City Council voted unanimously in January 2020 to make the investigation and arrest for adult possession, use or cultivation a low-priority infraction (https://ibn.fm/YlVE9). In another unanimous vote in September 2020, Ann Arbor, Michigan’s City Council voted in favor of declaring the investigating and arrest of anyone for planting, cultivating, purchasing, transporting, distributing, engaging in practices with or possessing psilocybin the city’s lowest law enforcement priority (https://ibn.fm/pooRa). All four cities citied indigenous cultural reasons as well as research around the use of psychedelics in the treatment of mental health and as a viable option combating the opioid crisis.
More movement is being seen in the decriminalization and push for research across the United States.
- Alexandria Ocasio-Cortez filed legislation for researchers to more easily study the benefits of psychedelic drugs (https://ibn.fm/vDEHF)
- Jeff Shipply filled a bill in the name of personal freedom to decriminalize psilocybin in Iowa
- Initiative 81, voted on by D.C. residents and awaiting review by Congress, makes the possession and use of certain psychedelic plants low priority for the police (https://ibn.fm/yT730)
Criminalization and the stigmas attached have made it difficult for researchers to explore the medical benefits of psilocybin and other psychedelics. As more states accept the cultural and medical benefits of these substances, more research can be done, which could ultimately lead to increased health and well-being of Americans who are facing a mental health crisis on epic levels.
With more than 17 million people in the Unted States experiencing at least one major depressive episode (https://ibn.fm/0Wxky), it is past time for new treatment alternatives. Cybin is at the forefront of companies conducting clinical trials for potential new treatment options and is developing innovative approaches to bring new psychedelic-based therapies to patients in need.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, will be participating in the 10th annual LifeSci Partners Corporate Access Event. As part of the company’s participation, AzurRx president and CEO James Sapirstein will present a summary of the company’s business and clinical-development programs to any interested parties. His presentation will also include expected 2021 highlights. In addition, Sapirstein will participate in virtual one-on-one meetings with registered investors and pharmaceutical companies. The multiday event is scheduled for Jan. 6–8 and 11–14, 2021.
To register for the event, visit http://ibn.fm/JBmMH
To view the full press release, visit http://ibn.fm/3nbC6
About AzurRx BioPharma Inc.
AzurRx BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases. The company has a pipeline of three gut-restricted GI assets. The first is MS1819, a recombinant lipase biologic for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis, with two ongoing phase 2 clinical trials. The other two are clinical-stage therapies using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor: FW-420, for the treatment of grade 1 immune checkpoint inhibitor associated colitis (“ICI-AC”) and diarrhea in oncology patients, and FW-1022, for the treatment of COVID-19 gastrointestinal infections. The company is headquartered in Delray Beach, Florida, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.
NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at http://ibn.fm/AZRX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
According to Turkey news agency Anadolu, the country, which is located in Western Asia, has discovered an enormous gold deposit that holds roughly 99 tons of the valuable metal, which is roughly 3.5 million ounces. The gold deposit is valued at about $6 billion, totaling an estimated Rs 44,000 crore.
The gold deposit was found by Gübretaş, a fertilizer manufacturing firm, and reported by Turkey’s head of the agricultural credit cooperatives Fahrettin Poyraz. The deposit is located in Sögüt, a district and town located in Turkey’s Bilecik Province.
After news of the gold discovery became public, Gübretaş shares rose on the Turkish stock exchange, Borsa Istanbul, by about 10%. Poyraz stated in an interview with Anadolu that in two years, the first extraction of the precious metal would commence, which would add value to the economy of Turkey.
Poyraz stated that Gübretaş had won control of the site from another company in 2019 through a court-mandated decision. He added that Gübretaş was planning to develop the site. In addition to this, Poyraz noted that the company’s target for the coming five years was to attain an annual production of 100 tons.
Late in September 2020, Faith Dönmez, Turkey’s minister of Energy and Natural Resources reported that the country had broken its set target for the production of gold, by producing 38 gold tons.
The value of the recently discovered gold deposits is estimated to be larger than the gross domestic product of some nations. For instance, the GDP of Burundi is projected to be $3.17 billion, Lesotho’s GDP is $2.58 billion, Liberia’s GDP is $3.20 billion while that of the Maldives is pegged at $4.87 billion. This may make the deposit of gold richer than these nations. However, other countries such as Mauritania, Barbados, Montenegro and Guyana have economics that are significantly smaller than $6 billion.
A different development involving the inflow of funds into Turkey is the rehabilitation of the refugees from Syria. The European Union plans to inject nearly $590 million, which will be used to help over 1.8 million refugees and educate 7 million children. These programs are being managed by the Turkish Red Crescent in partnership with the Red Cross and UNICEF.
In the United States, Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) is a trendsetter in its own right. This Colorado-based firm is not only the largest uranium producer in the country, but it is also venturing into the production of badly needed rare earth elements.
NOTE TO INVESTORS: The latest news and updates relating to Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) are available in the company’s newsroom at http://ibn.fm/UUUU
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
- UUUU to receive minimum of 2,500 tons of natural monazite ore, one of highest-grade REE minerals in world
- Company to produce raw materials needed for clean energy, advanced technologies while also creating green jobs in economically underserved area
- Energy Fuels will be first U.S. company in years to produce marketable mixed REE concentrate on commercial scale
Energy Fuels (NYSE American: UUUU) (TSX: EFR), a diversified uranium miner, has finalized a three-year agreement with the Chemours Company (NYSE: CC) to obtain natural monazite ore, one of the highest-grade rare earth element (“REE”) minerals in the world (https://ibn.fm/Rp4YN). The agreement calls for Energy Fuels to receive a minimum of 2,500 tons per year and represents a significant step in UUUU’s commitment to be a leader in re-establishing a fully integrated U.S. REE supply chain.
“With our announcement . . . Southeast Utah is fast becoming America’s clean energy and critical minerals hub,” Energy Fuels president and CEO Mark S. Chalmers stated. “Our goal is to domestically produce the raw materials needed for clean energy and advanced technologies, while creating green jobs in an economically challenged part of the country.
“Currently, the U.S. imports nearly all of our rare earth, uranium and vanadium requirements, despite having ample supplies here in the U.S.,” Chalmers continued. “Importantly, in the United States we are highly regulated and operate to the highest standards, which means we produce these minerals more responsibly than many of the countries from which we currently import. Our agreement with Chemours may be the beginning of a real success story, not only for Energy Fuels, but also for local communities, Native Americans, conservation groups, the State of Utah, and the U.S. as a whole.”
Based on the announcement, Energy Fuels intends to start process the monazite it receives from Chemours beginning the first quarter of 2021. The process will take place at UUUU’s wholly owned White Mesa Mill, which is located in Utah. The company will recover the uranium that results from that process and produce a marketable mixed REE carbonate, an essential step toward re-establishing a fully independent U.S. REE supply chain.
Once Energy Fuels successfully begins this process, UUUU will be the first company in the United States in years to produce a marketable mixed REE concentrate ready for separation on a commercial scale. Based on its estimates, UUUU plans to be able to provide almost 10% of total current U.S. REE demand. REEs are used in a wide variety of clean energy and advanced technologies, including wind turbines, electric vehicles, cell phones, computers, flat-panel displays, advanced optics, catalysts, medicine and national defense applications.
Energy Fuels’ mixed REE carbonate production from monazite ore should use only a small amount of its White Mesa Mill’s ore-production capacity and produce almost no waste. Initially, UUUU plans on obtaining the 2,500 tons of monazite sands from Chemours, as outlined in the contract, but the company will work to increase monazite ore supply, hopefully reaching approximately 15,000 tons of monazite ore per year. The White Mesa Mill is licensed and designed to process 2,000 tons of ore daily, or 720,000 tons of ore per year, so the anticipated production of monazite sands represents an estimated 2% of its throughput capacity. If successful at reaching those numbers, Energy Fuels projects its White Mesa Mill will be able to produce approximately 50% of U.S. REE demand in a mixed REE carbonate.
For more information, visit the company’s website at www.EnergyFuels.com.
NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has been selected by a subsidiary of a U.S.-based Fortune 500 technology and engineering company to provide its digital therapeutics solution to eligible employees. DarioHealth’s partnership with Vitality Group made this agreement possible, which is DarioHealth’s first client in the self-insured employer market. One of the largest wellness companies in the world, Vitality Group blends industry-leading smart tech, data, incentives and behavioral science to inspire healthy changes in individuals and their organizations; an estimated 20 million people in 26 markets engage in the Vitality program. Under the announced agreement, members of the Fortune 500 subsidiary are expected to begin enrollment this month; those members will be eligible to receive Dario’s diabetes and hypertension solution. “We are very pleased that our digital therapeutic solution has been selected by one of Vitality Group’s clients,” said DarioHealth president and general manager Rick Anderson in the press release. “We believe that this represents another employer that recognizes the benefits of our industry-leading chronic condition solutions, high level of member satisfaction, ease of integration and commitment to transparent approach to only charging for engaged members. We look forward to working with them to assist their members living with diabetes and hypertension to improve their health and thereby reducing the cost of care.”
To view the full press release, visit http://ibn.fm/TB6LE
About DarioHealth Corp.
DarioHealth is a leading global, digital-therapeutics company revolutionizing how people with chronic conditions manage their health. By delivering evidence-based interventions driven by connected devices, data, high-quality software and coaching, the company makes the right thing to do the easy thing to do. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology. Dario offers one of the highest-rated diabetes and hypertension solutions on the market; its highly engaging, user-centric MyDario(TM) mobile app is used regularly by tens of thousands of consumers worldwide. The company is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
MENLO PARK, Calif., Jan. 05, 2021 — 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the “Company”), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that the Company will present at the H.C. Wainwright Bioconnect 2021 Conference.
The presentation will be available on-demand through the Conference from January 11-14, 2021 starting at 6:00 a.m. ET.
A webcast of the presentation will also be available at the following link: https://journey.ct.events/view/479a72c6-8d48-4a89-b6ba-07b08d34cee1 , and in the IR section of the Company’s website. The webcast will be archived and accessible on the website for at least 90 days.
About 180 Life Sciences Corp .
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The Company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Company’s primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor), with its lead program in phase 2b/3 clinical trials.
Forward-Looking Statements
This press release includes “forward-looking statements”, including information about management’s view of the Company’s future expectations, plans and prospects, within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 (the “Act”). Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results and, consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements and factors that may cause such differences include, without limitation, statements relating to the continued listing of the Company on The NASDAQ Stock Market; expectations regarding the capitalization, resources and ownership structure of the Company; expectations with respect to future performance, growth and anticipated acquisitions; the ability of the Company to execute its plans to develop and market new drug products and the timing and costs of these development programs; estimates of the size of the markets for its potential drug products; potential litigation involving the Company or the validity or enforceability of the intellectual property of the Company; global economic conditions; geopolitical events and regulatory changes; access to additional financing, and the potential lack of such financing; and the Company’s ability to raise funding in the future and the terms of such funding. These risk factors and others are included from time to time in documents the Company files with the Securities and Exchange Commission, including, but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks, as well as in the definitive proxy statement/prospectus that the Company filed in connection with the recent merger. These reports and filings are available at www.sec.gov. All subsequent written and oral forward-looking statements concerning the Company, the transactions described herein or other matters and attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as otherwise provided by law.
Investors :
Jason Assad
Director of IR
180 Life Sciences Corp
678-570-6791
Jason@180lifesciences.com
Media Relations:
David Schull
David.Schull@russopartnersllc.com
(212) 845-4271
Eric Ando
Eric.Ando@russopartnersllc.com
(646) 218-4604
Obesity during childhood is a challenge for many children. However, there may be hope, as German researchers have discovered that social, environmental and behavioral factors influence weight loss significantly, while obesity genes play a minor role in successful weight loss.
The recent study carried out by the Technical University of Munich (TUM) suggests that there are vital things to consider with regard to treatment strategies for obesity in children. Melanie Heitkamp, a researcher from TUM’s department of prevention, sports medicine and rehabilitation, explained that using an individual’s genetic predisposition as a basis for their likelihood to respond to a treatment for obesity may not help the treatment in succeeding.
Heitkamp, who is also the study author, added that even people who carried risk variants of genes connected with obesity would derive benefit from a healthy lifestyle, which included regular physical activity and a calorie-balanced diet.
The study involved more than 1,400 young individuals between the ages of 6 and 19 who were either obese or overweight. The study participants were enrolled in a four- to six-week program comprised of behavioral therapy, physical activity every day and a diet that was calorie restricted. In addition to this, the scientists also examined the genes of about 1,200 of the individuals involved in the study.
Heitkamp stated that some individuals had a rare obesity form that was brought about by single-gene defects. However, no one gene could be identified in a majority of people as the main cause of obesity. Furthermore, she explained that the interaction between an individual’s unhealthy lifestyle and genetics contributed to obesity. More than 900 gene variants that had been identified in various studies were linked to obesity.
Heitkamp also noted that genome studies had discovered 97 loci on human chromosomes that were linked to obesity at the time her team was conducting a statistical analysis. Further study had brought the number of those locations lower, to 56.
The scientists discovered that of the five statistically significant gene variants, three were linked to greater weight loss during the study duration. This meant that individuals who were carriers of the at-risk genes lost more weight through the lifestyle changes adopted than expected. The study’s results were reported in an online “JAMA Pediatrics” article.
However, the researchers believe that more studies need to be conducted to determine whether other genes that are not linked to obesity may also influence weight loss.
Still on the matter of combating threats to health, Predictive Oncology (NASDAQ: POAI) deserves special mention. Using its relationships with the industry’s movers and shakers, the company is in the process of developing tools to better diagnose and assess the progress of thyroid cancer so that treatment can be better targeted or customized.
NOTE TO INVESTORS: The latest news and updates relating to Predictive Oncology (NASDAQ: POAI) are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that it has hired an investor relations firm. POAI has chosen Landon Capital to provide investor relations services; the agreement was effective Dec. 30, 2020. The announcement noted that anticipated services would include introductions to investors, financial and industry analysts, registered brokers and financial writers. Those introductions would be made with the intent to provide interested individuals and groups with information about POAI’s business strategy, developments and accomplishments. The announcement also noted that Landon Capital would assist POAI in the development of a database of individuals, financial institutions and other entities with possible interest in obtaining publicly available information related to POAI; in addition, Landon Capital will assist in providing that information.
To view the full press release, visit http://ibn.fm/uJ4ZM
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information about the company, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights to publicly traded companies through its software-as-a-service (“SaaS”) platform, Sequire, today announced that Lou Kerner will be appointed chief executive officer of its wholly owned subsidiary BIGtoken. SRAX previously announced its entry into a definitive agreement with Force Protection Video Equipment Corp (OTC: FPVD), pursuant to which SRAX will receive 88.9% of the issued and outstanding shares of FPVD in exchange for 100% of the shares of BIGtoken. FPVD will be renamed BIGtoken Inc. with Kerner as its CEO upon completion of the transaction. “Lou has been working with data and internet startups his entire career. He has a detailed understanding of blockchain and how it is applied to augment business applications. Blockchain will play a big part in the future of consumer identity and privacy and we have a shared vision with Lou on what this will look like,” said Christopher Miglino, CEO of SRAX. “Not only is Lou a technology expert, but his knowledge of the capital markets will be a significant asset to BIGtoken as the company is uplisted to a nationally listed exchange.”
To view the full press release, visit http://ibn.fm/FbcEV
About SRAX Inc.
SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com and MySequire.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
The transport sector accounts for around 28.2% of total carbon emissions in North America. In a bid to cut down these emissions, reduce reliance on fossil fuels and improve air quality, several state governments have been considering banning the sale of new internal combustion engine vehicles in exchange for electric vehicles (“EVs”). Powered by clean, renewable energy, EVs produce zero emissions at the tailpipe, making them perfect for drivers keen on reducing their carbon footprint.
However, EV adoption is far from universal, with the high upfront costs and range anxiety keeping most drivers from making the switch to electric vehicles. This is corroborated by a new “Consumer Reports” survey, which found that most U.S. drivers are interested in going green but have been held back by expensive costs and insufficient charging infrastructure. More than 70% of the surveyed drivers expressed interest in purchasing an electric vehicle, while 27% said they would consider getting an EV as their next vehicle and 4% said they were planning on making an EV their next vehicle.
When they were asked to choose from a list of the factors that concerned them most about purchasing an electric vehicle, 5 out of 10 drivers chose “not enough charging stations.” Additionally, most respondents said that policy actions such as installing public charging stations along highways would make them more willing to lease or buy an EV. Respondents also asked for more government incentives to make EVs as affordable as internal combustion vehicles, with 60% of respondents supporting state and federal incentives for all consumers, while 12% opposed.
The surveyed drivers were also in favor of a more diverse range of all-electric models, with 7 out of 10 respondents saying that they would like automakers to offer electric powertrains in more vehicle models including full-size SUVs and pickup trucks. Only 4% of the respondents opposed the idea, meaning automakers such as Rivian, Tesla, Ford and General Motors that have been developing electric pickups are on the right track.
The “Consumer Report” survey found results similar to a 2019 poll commissioned by Volvo. That poll surveyed 1,510 U.S. drivers in October 2018; 61% of those respondents said insufficient charging infrastructure holds them back from purchasing EVs. Other results indicate that 58% of the respondents said they were worried about running out of juice on the road, and 57% said they would consider purchasing an EV if it didn’t cost much more than a conventional car.
The future of EVs seems to be bright, and it is no wonder that the industry is seeing a flurry of investor activity. For instance, Net Element (NASDAQ: NETE) is in the process of completing a reverse merger with Mullen Technologies Inc., a maker of electric vehicles in California.
NOTE TO INVESTORS: The latest news and updates relating to Net Element (NASDAQ: NETE) are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
iClick Interactive Asia Group (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, today announced the addition of Philip Kan to its board of directors, effective Jan. 1, 2021. Per the update, Kan will chair iClick’s Nominating and Corporate Governance Committee. “The addition of Philip to the board will help bring additional guidance and leadership for iClick at the stage of our continued growth,” said Jian “T.J.” Tang, iClick’s CEO and co-founder. “Philip brings tremendous business experience, much of it in management and leadership roles in the financial sector in Hong Kong and mainland China that will be highly relevant and additive to us as we continue to grow our integrated data-driven solutions offerings both internally and through M&A opportunities. We look forward to leveraging his insights to achieve our corporate goals.”
To view the full press release, visit https://ibn.fm/tzXsP
About iClick Interactive Asia Group Limited
iClick Interactive Asia Group is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, iClick’s proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in ten locations worldwide, including Asia and Europe. For more information about the company, please visit ir.i-Click.com.
NOTE TO INVESTORS: The latest news and updates relating to ICLK are available in the company’s newsroom at http://ibn.fm/ICLK
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Energy Fuels (NYSE American: UUUU) (TSX: EFR), a leading producer of uranium in the United States, on Thursday announced that it has filed a prospectus supplement to its effective U.S. registration statement on Form S-3 in order to renew its “at-the-market” (“ATM”) program. Under the program, the company may, at its discretion from time to time, sell up to an additional US$35.0 million of common shares, with sales only being made on the NYSE American at then-prevailing market prices, or any other existing trading market of the common shares in the United States. The prospectus supplement and the accompanying base shelf prospectus relating to this offering have been filed with the U.S. Securities and Exchange Commission (“SEC”) and are available on the SEC’s website at www.sec.gov.
To view the full press release, visit http://ibn.fm/CVxpj
About Energy Fuels Inc.
Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and anticipates commencing commercial production of rare earth element (“REE”) carbonate in 2021. Its corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, has the ability to produce vanadium when market conditions warrant and is completing final test-work for the production of REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” For more information, visit the company’s website at www.EnergyFuels.com.
NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Creatd (NASDAQ: CRTD, CRTDW), the parent company of Vocal, has closed its previously announced private placement of equity. According to the update, Creatd secured approximately $7.77 million in gross proceeds from the sale of 7,778 shares of its Series E Convertible Preferred Stock and accompanying warrants to existing shareholders and new institutional investors. The company intends to use the net proceeds to satisfy Nasdaq’s stockholders’ equity listing requirements as well as to further accelerate its business plan, social media and digital marketing initiatives; repay all of its remaining debt; fund accretive acquisitions; and fulfill other operational working capital needs. The Special Equities Group, a division of Bradley Woods & Co. Ltd., acted as exclusive placement agent for the transaction. “I am personally grateful for the support of our shareholders, who quickly came together to provide funding over the course of just a few days during the holiday period,” said Jeremy Frommer, founder and CEO of Creatd. “With our funding needs met, management now enters the new year fully focused on accelerating the growth and reach of our Vocal platform, without the distraction of immediate cash flow constraints. Going forward, with a strengthened balance sheet and our talented management team, board of directors, and advisory group, we are prepared and well-equipped to achieve profitable growth during 2021.”
To view the full press release, visit http://ibn.fm/W6yRW
About Creatd Inc.
Creatd empowers creators, brands and entrepreneurs through technology and partnership. Its flagship technology, Vocal, is a best-in-class creator platform. For more information about Creatd and its Vocal platform, visit www.Creatd.com and www.Vocal.media.
NOTE TO INVESTORS: The latest news and updates relating to CRTD are available in the company’s newsroom at http://ibn.fm/CRTD
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- Neuro-oncology drug developer CNS Pharmaceuticals is completing an underwritten public offering of common stock shares and warrants in a bid to fund its upcoming Phase 2 trials for a candidate in fighting glioblastoma brain cancers
- CNS’s Phase 2 trials are scheduled to begin during Q1 of 2021, building on a Phase 1 trial in which 44 percent of patients saw improvement and one patient has survived cancer-free for nearly 15 years
- The company has designed an ambitious, adaptive trial that allows for an interim analysis of data and adjustments for efficiency in bringing the drug candidate, Berubicin, to hoped-for approval as a glioblastoma treatment
- CNS is aiming for FDA approval of an expedited development pathway to obtain maximum efficiency in its timeline
- A recent syndicated broadcast provided CNS with additional publicity, shining a spotlight on its achievements in obtaining FDA approval for Investigational New Drug (“IND”) status
The dawning of a new year is traditionally a time when people embrace the hope of new promise in defeating the disappointments of the past months, and the advent of 2021’s calendar is perhaps more so than ever as a growing number of vaccines against the worldwide COVID-19 pandemic begin to roll out to the public in tiered priority phases.
Also just over the new year’s horizon is the launch of Phase 2 testing by neuro-oncology biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) as CNS advances an ambitious agenda for developing a drug candidate that has shown promise in the fight against glioblastoma, a deadly brain cancer that has no known cure or longevity-building treatment.
CNS’s drug candidate Berubicin was the focus of another company’s Phase 1 safety trials nearly 15 years ago. Out of 25 trial participants in the 2006 analysis, 11 of them (44 percent) achieved “statistically significant improvement in clinical benefit” and one of them continued to survive completely cancer-free as of last Feb. 20, when the most recent patient evaluation was conducted. Since glioblastoma patients have a median survival rate of only 14.6 months from the date of the malignancy’s diagnosis, the patient’s response has excited interest in Berubicin’s potential (https://ibn.fm/8wVG3).
CNS recently conducted an underwritten public offering of 5 million shares of common stock as well as warrants to purchase up to 2.5 million shares of common stock, selling the stocks and warrants together at a combined public offering price of $2 per share and warrant to fund the upcoming Phase 2 trial as well as other research and development. CNS also granted the underwriter a 45-day option to purchase up to an additional 750,000 shares of common stock and/or 375,000 warrants to cover over-allotments, if any occur. The offering was expected to close on or about Dec. 28 (https://ibn.fm/4j2B5).
“Anthracyclines as a class of chemotherapy have been used for over 60 years to treat a variety of cancers. … However, historically, anthracyclines have never been used to treat primary or metastatic brain cancers because scientists could not demonstrate that anthracyclines were able to cross the blood-brain barrier and achieve significant levels of activity in the brain,” CEO John Climaco said during a recent webinar (https://ibn.fm/c1d6K). “Berubicin may change that history because it is the first anthracycline that, based on limited clinical data, appears to cross the blood-brain barrier and achieve drug levels critical for efficacy against central nervous system malignancies.”
The U.S. Food and Drug Administration (“FDA”) approved CNS’s Investigational New Drug (“IND”) application for Berubicin shortly before Christmas, and the company’s success in that endeavor was highlighted in a recent broadcast via NetworkNewsAudio (“NNA”) to thousands of syndication points (https://ibn.fm/F8N5C).
“Since becoming a public company, our clear focus has been on advancing the clinical development of Berubicin. We will now rapidly move to initiate our Phase 2 trial of Berubicin for adults with GBM and expect to begin enrolling patients in the first quarter of next year,” Climaco stated in a news release about the broadcast. “The Company will transform within the next several months as Berubicin becomes the subject of up to three active clinical trials, which include our randomized, controlled Phase 2 trial in the U.S., and 2 trials planned by our sublicensee WPD in Poland.”
The trial’s adaptive, stage-progressive design is intended to allow an interim analysis of the data for efficacy and then to allow an adjustment in patient population if necessary to make the most efficient and rapid use of time. CNS anticipates its trial strategy may potentially grant it an expedited pathway for development with the FDA if it continues to be successful.
For more information, visit the company’s website at www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently hosted a webinar to discuss the clinical design for its upcoming Phase 2 trial. The trial will study its lead drug candidate, Berubicin, for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of brain cancer currently considered incurable. Berubicin is an anthracycline that has demonstrated significant potential to effectively cross the blood-brain barrier and target central nervous system malignancies. The company’s Phase 2 trial will recruit 243 patients for side-by-side, real-time analysis of Berubicin’s performance against lomustine, the chemotherapy standard of care drug. “We are evaluating responses defined as a decrease in the size of the tumor, as well as stability of the disease defined as no further increases in the size of the tumor once the patient is put on study, as well as the time to progression of these tumors and importantly overall survival of the patients,” CMO Dr. Sandra Silberman said during the webinar.
To view the full article, visit: https://ibn.fm/jqKgo
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a leading producer, developer and operator of augmented reality (“AR”) interactive entertainment games, toys and educational materials in China, today announced that its subsidiary, Xunpusen Technology Co. Ltd., generated approximately RMB30 million (approximately USD $4.5 million) in revenue in the first four months of operation. According to the update, the company has continued to develop and utilize Xunpusen’s mobile marketing and hosting expertise to both support and grow Blue Hat’s traditional mobile and gaming business while seeking new channels to expand its customer base and leverage relationships. “We are very pleased with the development of Xunpusen,” said Xiaodong Chen, CEO of Blue Hat. “Initially, our goal was to utilize direct marketing and sales techniques to further our relationships with larger companies and increase sales of Blue Hat’s core product portfolio. The deployment of 5G technology, coupled with the acceleration of mobile utilization throughout 2020 has also created opportunities in the internet data center business. We expect that the recent agreement with China Mobile will lead to further agreements due to the surge in data volume and the strong downstream demand. We will keep investors closely apprised of our progress.”
To view the full press release, visit http://ibn.fm/fA1sC
About Blue Hat
Blue Hat Interactive Entertainment Technology is a producer, developer and operator of AR interactive entertainment games and toys in China, including interactive educational materials, mobile games and toys with mobile-game features. The company’s entertainment platform creates unique user experiences by connecting physical items to mobile devices, which creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users. For more information, please visit the company’s investor relations website at www.IR.BlueHatGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal (“GI”) diseases, today announced its entry into an exclusive worldwide licensing agreement with First Wave Bio Inc. for the use of its patented and proprietary oral and rectal formulations of niclosamide for the treatment of immune checkpoint inhibitor-associated colitis (“ICI-AC”) and COVID-19 GI infections. “The acquisition of rights to niclosamide for these indications gives us an opportunity to strategically expand our existing pipeline and pursue multiple GI indications in the oncology and infectious disease arenas,” said James Sapirstein, president and CEO of AzurRx. “We are impressed with First Wave’s Phase 1b/2a clinical data, strong IP and patent position, and the significant unmet medical needs and market opportunities addressed by these two assets. We believe these niclosamide formulations could offer significant advantages over other currently available treatments. They are not systemically absorbed, potentially allowing for higher local GI concentrations of drug delivery and avoiding steroid-related immunosuppressant complications.”
In addition, the company announced that, in conjunction with its exclusive agreement with First Wave, it has entered into a securities purchase agreement with a single health care-focused institutional investor, under which the company agreed to sell approximately $8.0 million of Series C 9.00% Convertible Junior Preferred Stock in a registered direct offering and concurrent private placement. The company will also issue to the investor unregistered warrants to purchase up to an aggregate of 10,666,668 shares of common stock. H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.
To view the full press releases, visit http://ibn.fm/Dws3k and http://ibn.fm/PgjPr
About AzurRx BioPharma Inc.
AzurRx BioPharma is a biopharmaceutical company specialized in the research and development of non-systemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial, and the Combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. The company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.
NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at http://ibn.fm/AZRX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Loop Insights (TSXV: MTRX) (OTCQB: RACMF), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement and automated venue tracing to the brick-and-mortar space, today announced that Internet of Things (“IoT”) partner Telus Corporation (TSX: T) (NYSE: TU) is accelerating its partnership with Loop Insights in 2021. Under the collaboration, Telus will launch a direct and indirect national sales and marketing campaign showcasing Loop’s IoT solutions stack. In addition to leveraging its own nationwide marketing tools and direct sales force, Telus is also launching an expanded campaign through The Acquisition Group (“TAG”). “It has been a great experience working with the Telus team and the great support we have received since we officially started working together in October,” said Loop Insights CEO Rob Anson. “Today’s commitment to significantly expanded sales and marketing is a great show of confidence and even greater validation of our capabilities. Since the launch of our second product in the Telus IoT Marketplace in December, there has been a great level of interest in our product line and we are looking forward to a very strong roll out now with the addition of The Acquisition Group.”
To view the full press release, visit http://ibn.fm/Nkrlz
About Loop Insights Inc.
Loop Insights is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing and contactless solutions to the brick-and-mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network. For more information, visit the company’s website at www.LoopInsights.ai.
NOTE TO INVESTORS: The latest news and updates relating to RACMF are available in the company’s newsroom at http://ibn.fm/RACMF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
